Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study Authors: Yoshiki Hanaoka, Tsubasa Takizawa, Ryotaro Ishii, Daisuke Danno, Masayuki Hamakawa, Kaname Ueda, Yoshinori Tanizawa, Satoshi Osaga, Leo J Philip Tharappel, Chie Hashimoto Published: 2026 ABSTRACT AbstractBackgroundCalcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are an effective preventive treatment for migraine. However, their population-level utilization patterns and treatment gaps are underreported in Japan. This analysis of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) 2nd study, evaluated utilization patterns of CGRP mAbs and treatment gaps, and identified factors associated with CGRP mAb treatment experience among CGRP mAb-eligible individuals with migraine in Japan.MethodsThis analysis of a nationwide, population-based, cross-sectional online survey included adults with migraine. Respondents were further classified according to CGRP mAb eligibility (based on the guidelines for the promotion of optimal use). Both CGRP mAb-eligible and ineligible individuals were stratified by experience with CGRP mAbs. CGRP mAb-experienced respondents were further stratified into “current CGRP mAb” and “discontinued CGRP mAb” subgroups. Respondents reported their CGRP mAb utilization pattern, headache perceptions, attitude, and barriers to treatment initiation. Multivariate logistic regression was performed to identify the factors associated with CGRP mAb treatment experience among CGRP mAb-eligible respondents.ResultsAmong the 19,590 respondents with migraine, 1484 (7.6%) met the eligibility criteria for CGRP mAbs (78 were current CGRP mAb users, 58 discontinued CGRP mAb, and 1348 never used CGRP mAbs), indicating about 90% of CGRP mAb-eligible individuals had never received CGRP mAb therapy. Among the 18,106 CGRP mAb-ineligible respondents, based on the current symptom status at the time of the survey, 110 were current CGRP mAb users, 176 discontinued CGRP mAbs, and 17,820 never used CGRP mAbs. In both the eligibility groups, more CGRP mAb-experienced respondents visited CGRP mAb-prescribable departments (63.6–88.5%). Among the CGRP mAb-eligible current users, most had consulted headache specialists (40.5%), and the proportion of triptan use (ever and current) was also high in these groups (84.6% and 73.1%). Among eligible nonusers (n = 1348), awareness of CGRP mAbs was markedly low (78.0% had never heard of CGRP mAbs), and only 4.2% had been informed about CGRP mAbs by a physician. Eligible nonusers were less likely to discuss treatment goals with physicians and more likely to perceive migraine as an unavoidable condition. Among the eligible respondents, CGRP mAb treatment experience was strongly associated with prior triptan use (OR 9.38 [95% CI 5.94, 14.80]), and consultation at the CGRP mAb-prescribing department (OR 7.20 [95% CI 3.60, 14.37]).ConclusionsA substantial treatment gap exists in the use of CGRP mAbs among eligible individuals with migraine in Japan. Improving access to specialist care, enhancing patient-physician communication, and increasing awareness of preventive treatment options are critical to address the unmet treatment needs.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s40801-026-00571-9. Key Points Real-world evidence on CGRP mAbs is largely limited to clinical effectiveness and safety, leaving population-level utilization patterns and treatment gaps underreported.This population-based analysis revealed that about 90% of CGRP mAb-eligible individuals with migraine in Japan, based on the current symptom status at the time of the survey, had never received CGRP mAb therapy, highlighting a major treatment gap driven by low patient awareness, limited access to CGRP mAb-prescribing specialists, and insufficient physician-patient communication about treatment options and goals.Improving specialist referrals, raising awareness on standard migraine therapy, and ensuring access to treatment options based on appropriate clinical judgments are essential to addressing the unmet treatment needs of people with migraine in Japan. Introduction Migraine, a chronic multifactorial neurologic disorder, is characterized by recurrent and pulsating headache with moderate-to-severe pain which is worsened by physical activity [1]. The prevalence of migraine in Japan is 7.3–8.4% [2, 3]. It is a highly disabling condition for many individuals, as it is not only physically painful, but also impacts overall well-being and health [4]. Multiple real-world studies in Japan have reported the burden of migraine with respect to reduced work productivity [5–9], poor health-related quality of life (HRQoL) [5–10], and high healthcare resource utilization (HCRU) [8, 9]. Furthermore, an increase in monthly headache days (MHD) tends to exacerbate HRQoL and work productivity, while increasing HCRU and indirect costs [6, 8]. Hence, managing migraine and reducing its progression with appropriate treatment is essential [6, 8]. Early onset of migraine prevention also reduces the number of headache/migraine attacks, headache/migraine hours, and headache/migraine days, as well as improves function, HRQoL, and disability [11]. Calcitonin gene-related peptide (CGRP) is a potent vasodilatory peptide present in the peripheral and central nervous system [12]. In the trigeminovascular system, CGRP has been associated with the pathophysiology of migraine [12, 13]. CGRP monoclonal antibodies (CGRP mAbs) such as galcanezumab, fremanezumab, and erenumab, inhibit the CGRP pathway by either binding to the CGRP ligand or the CGRP receptor [14]. These CGRP mAbs have been available in Japan for the prevention of migraine since 2021 [15], and their real-world effectiveness in Japan has been widely reported [16–28]. Guidelines for the promotion of optimal use (OUGL) of CGRP mAbs in Japan are also available [29–31]. The Japanese Headache Society (JHS) Clinical Practice Guideline for Headache Disorders 2021 recommends multiple acute and preventive treatments, with preventive treatment recommended for individuals with ≥ 2 migraine attacks per month or ≥ 3 days of headache attacks per month that impact daily life [32]. Furthermore, OUGL for CGRP mAbs recommend these treatments only for patients who have experienced ≥ 1 oral preventive treatment failure [29–31]. These stringent criteria, relatively high drug cost [33–35], and inadequate timely medical intervention [6], may limit patient access to CGRP mAbs. This may have resulted in the low prescription of CGRP mAbs in Japan, as claims database studies from 2018 to 2022 or 2023 and the 2023 ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) 2nd study reported that only 0.4–2.2% of individuals with migraine in Japan received CGRP mAbs [6, 36, 37]. A similar pattern of CGRP mAb prescription (1.7%) was reported in a real-world study from Spain [38]. In contrast, data from the OVERCOME (US) study showed that 5.0% of respondents with migraine were CGRP mAb ever users, indicating a slightly higher uptake in the US [39]. However, in October 2025, the JHS released a position statement recommending CGRP-targeting therapies (including CGRP mAbs and gepants) as first-line therapy for migraine prevention [40]. This change in prescribing guidelines may increase patient access to CGRP mAbs. Since the launch of CGRP mAbs in Japan, numerous studies have reported their real-world effectiveness and safety based on clinical data from medical institutions [18–28], and prescription claims database studies have described treatment patterns among patients receiving care [36, 37]. However, these data sources are inherently limited to individuals who have accessed the healthcare system, leaving population-level utilization patterns, treatment gaps, and patient experiences or patient-reported outcomes (PROs) largely underreported. To address this knowledge gap, this analysis of the OVERCOME (Japan) 2nd study, a nationwide population-based survey, aimed to (1) evaluate the utilization patterns of CGRP mAbs and treatment gaps in people with migraine in Japan, and (2) identify factors associated with CGRP mAb treatment experience among CGRP mAb-eligible individuals. Methods Study Design Danno et al. [6] have described the study design of the OVERCOME (Japan) 2nd study earlier. Briefly, this observational, cross-sectional, nationwide, population-based online study used multiple online survey panels between June 2023 and August 2023 to recruit adults in Japan. In this survey, the distribution of respondents before migraine screening was designed to approximate the national age- and sex-composition. Participants were screened to create a sample that demographically matched the 2020 Japanese census data with respect to geographic region, gender, and age. To achieve this demographic balance, survey response collection was closed when a geographic region, gender, or age group reached the target quota. Eligible participants were divided into a migraine and non-migraine group after screening. The current analysis was only performed on participants in the migraine group. The Medical Corporation TOUKEIKAI Kitamachi Clinic ethics committee approved this study (number BGQ09531) on 19 April 2023. The study was conducted per ethical principles originating from the Declaration of Helsinki and was consistent with Good Pharmacoepidemiology Practices. All applicable Japanese laws and regulations were followed. All survey respondents provided electronic informed consent and agreed to participate in the study. All data were anonymized before analysis. The datasets generated and/or analyzed during the current study are available at Eli Lilly Japan K.K on reasonable request. Study Population and Selection Criteria Danno et al. [6] have previously explained the OVERCOME (Japan) 2nd study’s inclusion and exclusion criteria. Briefly, participants were ≥ 18 years old, Japanese residents, had experienced headaches or migraine in the past year, and either self-reported physician-diagnosed migraine or met modified criteria for migraine per International Classification of Headache Disorders—3rd edition (ICHD-3) criteria [1]. These criteria were validated in the American Migraine Study [41] and the American Migraine Prevalence and Prevention Study [42], as mentioned in other OVERCOME studies from various countries [5, 43, 44]. Participants were excluded if all headaches experienced in the past year were secondary headaches caused by trauma, infections, hangovers, or, if respondents’ provided inconsistent answers for gender and disease-related questions. Participants in the migraine group were further classified on the basis of their eligibility to receive CGRP mAbs. The CGRP mAb-eligibility was determined on the basis of the OUGL criteria for CGRP mAb use in Japan from the reimbursement perspective [29–31]. CGRP mAb-eligible individuals must have had ≥ 4 monthly headache days (MHDs), ≥ 1 oral preventive failure, and a Migraine Disability Assessment Scale (MIDAS) score of ≥ 6 or have had disability in daily life. In this study, oral preventive failure was determined by prompting respondents to check their medication record book for any of the drugs recommended by the JHS guidelines (including propranolol, valproate, lomerizine, topiramate, amitriptyline, etc.) [32]. The “≥ 1 oral preventive failure” criterion used for CGRP mAb eligibility in this study, per OUGL [29–31], was operationalized as the experience of using ≥ 1 of these physician-prescribed oral preventives, as a proxy. This study did not separately ascertain duration of use, dose, or reason for discontinuation (insufficient efficacy/tolerability/safety concerns). Disability was assessed using a questionnaire, with disability defined as any self-reported response indicating mild disability in work, household chores, or everyday activities; severe disability in work, household chores, or everyday activities but without the need to lie down to rest; or needing to lie down to rest. The respondents could self-report “normal or no disability” if they did not have any disability. Both CGRP mAb-eligible and ineligible individuals were stratified into groups based on CGRP mAb use. Those who had experience with CGRP mAbs were further stratified into “current CGRP mAb use” and “discontinued CGRP mAb” subgroups (Fig. 1). Since CGRP mAb eligibility was based on symptoms at the time of the survey, respondents whose symptoms had improved due to ongoing CGRP mAb treatment might have been classified as ineligible. Patients with any CGRP mAb experience (both current and discontinued) would, by definition, have met eligibility criteria at treatment initiation. Accordingly, the “eligible” group in this study reflects eligibility on the basis of current symptom status rather than clinical candidacy for CGRP mAb therapy. Study participants flow chart. (a) Targeted sampling to represent the Japanese adult population in terms of key demographic characteristics (age, sex, and geography) were applied. (b) This included those who passed the screener stage and represented the Japanese census adult population. (c) A quota of 2000 was set for the nonmigraine group and about 2000 respondents were randomly selected from the eligible population while preserving its demographic composition. The majority of respondents eligible for this group were over quota. (d) Represents a mixed population including (a) those whose symptoms improved due to treatment response, (b) those whose symptoms remitted spontaneously after discontinuation due to insufficient efficacy or adverse events. CGRP mAb calcitonin gene-related peptide monoclonal antibody, MHD monthly headache days, MIDAS Migraine disability assessment scale, n number of respondents, N total population Variables and Outcomes Participants self-reported demographic data such as age, sex, marital status, employment status, residential area, and annual household income. Participants also self-reported clinical characteristics, including MHDs in the past 90 days, and answered PRO instruments such as MIDAS [45, 46] (Japanese version [47]) and Migraine Interictal Burden Scale-4 (MIBS-4) [48, 49] (Supplementary Table S1). Necessary permissions to use MIDAS and MIBS-4 were obtained. Participants also self-reported the medical departments they visited in the past year, use of acute and preventive drugs, including CGRP mAbs, as well as reasons for not using CGRP mAbs referred by a physician, and discontinuation, suspension, resumption, and switching of CGRP mAbs. Medication experience and current use were captured via separate survey items. Patients were classified as “discontinued” if they reported prior experience with CGRP mAb but did not report current use. Among CGRP mAb users, another question determined whether they had a history of suspension and reinitiation; if they reported “yes,” the reasons for each were collected separately. CGRP mAb switching was defined as having used at least two different CGRP mAbs, with one being the currently prescribed treatment. Among participants meeting this definition, reasons for switching from the immediately preceding CGRP mAb to the current CGRP mAb were assessed. They also self-reported their attitude and perception of their headache, barriers to CGRP mAb initiation as well as their experience of discussing treatment goals with physicians. Statistical Analysis Data were summarized descriptively using mean and standard deviation (SD) for continuous variables and frequency and percentage for categorical variables. Data were reported based on CGRP mAb-eligibility or ineligibility, and no, current, or discontinued CGRP mAb use. Additionally, a two-step logistic regression approach was employed to identify factors associated with CGRP mAb treatment experience (ever used [current and discontinued groups] versus never used) among CGRP mAb-eligible respondents. First, univariate logistic regression analyses were performed to screen candidate explanatory variables, which included demographics (age, sex, region, marital status, employment status, and household income), clinical characteristics (age at headache onset, MHDs, migraine type, disability level, MIDAS total score, MIBS-4 score, and comorbidities), treatment history (over-the-counter medication, prescription NSAIDs, and triptan use), healthcare utilization (type of department consulted), and patient attitudes (experience discussing treatment goals, attitude toward headache management, and perception of preventive medication) (Supplementary Table S2). For each candidate explanatory variable reaching p < 0.05 in univariate screening, a separate multivariable logistic regression model was fitted, comprising that variable together with age and sex as fixed covariates; for variables other than the symptom measures, MHD was additionally included as an adjustment covariate, and the symptom measures (MIDAS total score and MIBS-4 score) were adjusted for age and sex only. Because the overlapping symptom indices (MHD, MIDAS, and MIBS-4) were not entered into the same model, collinearity among them did not arise. Results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). We performed two additional sensitivity analyses: variable selection sensitivity analysis to assess the robustness of the variable selection criterion using a p < 0.20 univariate entry threshold (a common alternative for variable screening in logistic regression) [50] and current user sensitivity analysis to identify the factors associated with ongoing treatment (eligible current CGRP mAb group versus eligible no CGRP mAb group) using the same two-step logistic regression approach, focusing on persistence rather than overall treatment exposure. The data were analyzed using Python Version 3.9.7 (Python Software Foundation) for categorical variables and BellCurve for Excel Version 4.04 or later (Social Survey Research Information Co., Ltd., Tokyo, Japan) for continuous variables and logistic regression analysis. Results Among the 19,590 respondents with migraine who completed the survey, 1484 (7.6%) met the eligibility criteria for CGRP mAb therapy at the time of the survey (Fig. 1). From the 1484 respondents, 136 (9.2%) had experience with CGRP mAbs (78 were current CGRP mAb users and 58 discontinued CGRP mAbs), and 1348 (90.8%) never used CGRP mAbs. Among the 18,106 respondents not eligible for CGRP mAbs based on the symptoms at the time of the survey, 286 (1.6%) had experience with CGRP mAbs (110 were current CGRP mAb users, and 176 discontinued CGRP mAbs), and 17,820 (98.4%) never used CGRP mAbs. Characteristics of the Respondents The majority of respondents were female in both the CGRP mAb-eligible group (68.2%) and the CGRP mAb-ineligible group (68.9%) (Table 1). However, the proportion of male respondents was numerically higher in the CGRP mAb-experienced groups, i.e., current and discontinued CGRP mAb users (38.5–60.2%) than in CGRP mAb nonuser groups (30.3–30.7%). The mean (SD) age of the CGRP mAb-eligible users ranged between 38.5 (9.8) and 41.5 (12.9) years, and CGRP mAb-ineligible users ranged between 35.9 (11.4) and 40.5 (13.2) years. Approximately 80% of respondents were employed in both the current and discontinued CGRP mAb-eligible and the CGRP mAb-ineligible groups. Table 1Demographic characteristics of the study respondentsVariableEligibleIneligibleNo CGRP mAb (n = 1348)Current CGRP mAb (n = 78)Discontinued CGRP mAb (n = 58)No CGRP mAb (n = 17,820)Current CGRP mAb (n = 110)Discontinued CGRP mAb (n = 176)Age (years), mean (SD)41.5 (12.9)39.0 (10.2)38.5 (9.8)40.5 (13.2)35.9 (11.4)36.5 (12.9)Sex, n (%)Female940 (69.7)48 (61.5)24 (41.4)12,358 (69.3)46 (41.8)70 (39.8)Male408 (30.3)30 (38.5)34 (58.6)5462 (30.7)64 (58.2)106 (60.2)Region, n (%)Hokkaido47 (3.5)1 (1.3)2 (3.4)686 (3.8)4 (3.6)6 (3.4)Tohoku98 (7.3)2 (2.6)5 (8.6)1063 (6.0)9 (8.2)6 (3.4)Kanto492 (36.5)35 (44.9)20 (34.5)6567 (36.9)40 (36.4)77 (43.8)Chubu196 (14.5)12 (15.4)13 (22.4)2980 (16.7)19 (17.3)28 (15.9)Kinki/Kansai218 (16.2)14 (17.9)9 (15.5)3028 (17.0)13 (11.8)28 (15.9)Chugoku86 (6.4)7 (9.0)3 (5.2)984 (5.5)7 (6.4)10 (5.7)Shikoku38 (2.8)2 (2.6)1 (1.7)517 (2.9)2 (1.8)5 (2.8)Kyushu/Okinawa173 (12.8)5 (6.4)5 (8.6)1995 (11.2)16 (14.5)16 (9.1)Marital status, n (%)Married590 (43.8)43 (55.1)36 (62.1)8066 (45.3)50 (45.5)96 (54.5)Single, never married537 (39.8)27 (34.6)17 (29.3)7582 (42.5)48 (43.6)62 (35.2)Divorced124 (9.2)5 (6.4)2 (3.4)1122 (6.3)3 (2.7)7 (4.0)Living with partner68 (5.0)1 (1.3)3 (5.2)728 (4.1)7 (6.4)9 (5.1)Widowed16 (1.2)2 (2.6)–195 (1.1)–2 (1.1)Prefer not to answer13 (1.0)––127 (0.7)2 (1.8)–Employment status, n (%)Employed947 (70.3)67 (85.9)50 (86.2)12,302 (69.0)88 (80.0)147 (83.5)Not employed401 (29.7)11 (14.1)8 (13.8)5518 (31.0)22 (20.0)29 (16.5)Annual household income, n (%) ≥ 5 million JPY552 (40.9)44 (56.4)40 (69.0)6912 (38.8)58 (52.7)114 (64.8) < 5 million JPY796 (59.1)34 (43.6)18 (31.0)10,908 (61.2)52 (47.3)62 (35.2)CGRP mAb calcitonin gene-related peptide monoclonal antibody, JPY Japanese Yen, n number of respondents, SD standard deviation Demographic characteristics of the study respondents CGRP mAb calcitonin gene-related peptide monoclonal antibody, JPY Japanese Yen, n number of respondents, SD standard deviation Headache-related and psychiatric comorbidities were more frequently reported among CGRP mAb-experienced eligible respondents (Table 2). Among eligible current users, depression and insomnia were reported by 38.5%, followed by 37.2% having tension-type headache. Among eligible discontinued users, depression and insomnia were observed in 32.8% and tension-type headache in 29.3%. Cardiovascular and metabolic comorbidities were more prevalent in discontinued users in both the eligible and ineligible groups. Among the eligible discontinued users, 46.6% had hypertension, 25.9% had dyslipidemia, and 24.1% had diabetes, while among the ineligible discontinued users, 38.1% had hypertension, 22.7% had diabetes, and 18.2% had dyslipidemia. Table 2Clinical characteristics of the study respondentsVariableEligibleIneligibleNo CGRP mAb (n = 1348)Current CGRP mAb (n = 78)Discontinued CGRP mAb (n = 58)No CGRP mAb (n = 17,820)Current CGRP mAb (n = 110)Discontinued CGRP mAb (n = 176)Comorbidities, n (%)Tension-type headache367 (27.2)29 (37.2)17 (29.3)1781 (10.0)21 (19.1)30 (17.0)Cluster headache97 (7.2)12 (15.4)10 (17.2)319 (1.8)11 (10.0)9 (5.1)Medication-overuse headache78 (5.8)16 (20.5)5 (8.6)153 (0.9)3 (2.7)2 (1.1)Depression367 (27.2)30 (38.5)19 (32.8)2592 (14.5)24 (21.8)34 (19.3)Anxiety/panic disorder252 (18.7)18 (23.1)11 (19.0)1623 (9.1)15 (13.6)22 (12.5)Insomnia297 (22.0)30 (38.5)19 (32.8)1701 (9.5)24 (21.8)40 (22.7)Hypertension257 (19.1)26 (33.3)27 (46.6)2184 (12.3)45 (40.9)67 (38.1)Diabetes101 (7.5)14 (17.9)14 (24.1)755 (4.2)17 (15.5)40 (22.7)Dyslipidemia229 (17.0)14 (17.9)15 (25.9)1993 (11.2)18 (16.4)32 (18.2)Average MHDs in the past 90 days, mean (SD)10.5 (7.0)10.9 (6.8)10.4 (6.1)3.0 (4.6)2.3 (3.4)1.7 (1.9)EM/CM, n (%)Episodic migraine1043 (77.4)56 (71.8)45 (77.6)17,167 (96.3)108 (98.2)176 (100.0)Chronic migraine305 (22.6)22 (28.2)13 (22.4)653 (3.7)2 (1.8)0 (0.0)Migraine severity, n (%)No/mild disability50 (3.7)1 (1.3)7 (12.1)3546 (19.9)16 (14.5)49 (27.8)Some disability688 (51.0)39 (50.0)29 (50.0)8865 (49.7)57 (51.8)94 (53.4)Severe disability236 (17.5)20 (25.6)7 (12.1)2112 (11.9)19 (17.3)13 (7.4)Requires bed rest374 (27.7)18 (23.1)15 (25.9)3297 (18.5)18 (16.4)20 (11.4)MIDAS total scorea, mean (SD)30.6 (38.3)39.9 (37.9)46.0 (38.9)8.1 (17.5)21.9 (29.1)16.8 (22.3)MIDAS gradeb, n (%)Grade I (0–5)300 (22.8)7 (9.3)4 (7.3)11,716 (66.0)27 (25.0)56 (32.4)Grade II (6–10)155 (11.8)9 (12.0)5 (9.1)2431 (13.7)23 (21.3)36 (20.8)Grade III (11–20)281 (21.3)17 (22.7)7 (12.7)1857 (10.5)22 (20.4)36 (20.8)Grade IV (21+)581 (44.1)42 (56.0)39 (70.9)1742 (9.8)36 (33.3)45 (26.0)MIBS-4 score, mean (SD)5.3 (4.0)6.2 (4.0)7.3 (3.5)3.0 (3.5)7.6 (3.4)7.1 (3.4)CGRP mAb calcitonin gene-related peptide monoclonal antibody, EM/CM episodic migraine/chronic migraine, MHD monthly headache days, MIDAS Migraine Disability Assessment Scale, MIBS-4 Migraine Interictal Burden Scale-4, n number of respondents, SD standard deviationaNumber of participants: Eligible, No CGRP mAb = 1317; Eligible, Current CGRP mAb = 75; Eligible, Discontinued CGRP mAb = 55; Ineligible, Current CGRP mAb = 108; Ineligible, Discontinued CGRP mAb = 173; Ineligible, No CGRP mAb = 17,746bGrade I (0–5): little or no disability; Grade II (6–10): mild disability; Grade III (11–20): moderate disability; Grade IV (21+): severe disability Clinical characteristics of the study respondents CGRP mAb calcitonin gene-related peptide monoclonal antibody, EM/CM episodic migraine/chronic migraine, MHD monthly headache days, MIDAS Migraine Disability Assessment Scale, MIBS-4 Migraine Interictal Burden Scale-4, n number of respondents, SD standard deviation aNumber of participants: Eligible, No CGRP mAb = 1317; Eligible, Current CGRP mAb = 75; Eligible, Discontinued CGRP mAb = 55; Ineligible, Current CGRP mAb = 108; Ineligible, Discontinued CGRP mAb = 173; Ineligible, No CGRP mAb = 17,746 bGrade I (0–5): little or no disability; Grade II (6–10): mild disability; Grade III (11–20): moderate disability; Grade IV (21+): severe disability Average MHDs in the past 90 days ranged from 10.4 to 10.9 days in CGRP mAb-eligible respondents and from 1.7 to 3.0 days in CGRP mAb-ineligible respondents (Table 2). While episodic migraine was predominant across groups (71.8–100%), a substantial proportion of respondents in the CGRP mAb-eligible groups had chronic migraine (22.4–28.2%). More than 70% of respondents across groups reported “some disability” or “worse” due to migraine. The mean [SD] MIDAS total score was highest among the CGRP mAb-eligible discontinued users (46.0 [38.9]), followed by eligible current users (39.9 [37.9]) (Table 2). The CGRP mAb-ineligible users had numerically lower mean MIDAS total scores. CGRP mAb-eligible groups had a numerically higher proportion of respondents with MIDAS grade IV (44.1–70.9%) than the CGRP mAb-ineligible groups (9.8–33.3%); discontinued CGRP mAb users had the highest proportion in CGRP mAb-eligible (70.9%) and current CGRP mAb users in CGRP mAb-ineligible groups (33.3%). The mean MIBS-4 scores ranged from 5.3 to 7.3 in the CGRP mAb-eligible groups and from 3.0 to 7.6 in the CGRP mAb-ineligible groups. Treatment patterns In both CGRP mAb-eligible and ineligible groups, numerically more CGRP mAb-experienced respondents visited CGRP mAb-prescribable departments (63.6–88.5%) than CGRP mAb-inexperienced respondents (19.5–56.9%) (Table 3). Furthermore, among CGRP mAb-eligible respondents with CGRP mAb experience, 40.5% of current CGRP mAb users and 34.0% of discontinued CGRP mAb users consulted headache specialists. Triptan use (ever used and current) were also high in these groups (56.9–84.6%). Table 3Treatment patterns of study respondentsEligibleIneligibleVariableNo CGRP mAb (n = 1348)Current CGRP mAb (n = 78)Discontinued CGRP mAb (n = 58)No CGRP mAb (n = 17,820)Current CGRP mAb (n = 110)Discontinued CGRP mAb (n = 176)Visited a medical institution in the past 1 year, n (%)936 (69.4)74 (94.9)53 (91.4)4389 (24.6)103 (93.6)129 (73.3)Top 3 departments visited in the past 1 yeara, n (%)1st placeGeneral practitioner396 (35.0)Headache Specialist30 (40.5)General practitioner24 (45.3)Generalpractitioner2253 (32.1)General practitioner45 (43.3)General practitioner53 (38.1)2nd placeNeurosurgery 177 (15.6)Neurology 28 (37.8)Headache Specialist 18 (34.0)Neurosurgery 639 (9.1)Neurology 30 (28.8)Neurosurgery 36 (25.9)3rd placeNeurology 155 (13.7)General practitioner27 (36.5)Neurology 11 (20.8)Neurology 499 (7.1)Neurosurgery 29 (27.9)Neurology 33 (23.7)CGRP mAb-prescribable department visits, n (%)767 (56.9)69 (88.5)48 (82.8)3466 (19.5)87 (79.1)112 (63.6)Acute treatment, n (%)Ever used OTC drugs1181 (87.6)66 (84.6)56 (96.6)15,404 (86.4)104 (94.5)171 (97.2)Current OTC drug use850 (63.1)46 (59.0)40 (69.0)12,290 (69.0)81 (73.6)137 (77.8)Ever used prescription NSAIDs843 (62.5)58 (74.4)51 (87.9)6314 (35.4)77 (70.0)123 (69.9)Current prescription NSAID use664 (49.3)44 (56.4)37 (63.8)4416 (24.8)57 (51.8)81 (46.0)Ever used triptans471 (34.9)66 (84.6)45 (77.6)1848 (10.4)88 (80.0)118 (67.0)Current triptan use354 (26.3)57 (73.1)33 (56.9)1132 (6.4)73 (66.4)82 (46.6)Preventive treatment, n (%)Ever used preventive drugs1348 (100)78 (100)58 (100)3268 (18.3)110 (100)176 (100)Ever used oral preventive drugs1348 (100)78 (100)58 (100)3171 (17.8)96 (87.3)162 (92.0)Current preventive drug use717 (53.2)78 (100)41 (70.7)1553 (8.7)110 (100)129 (73.3)Current oral preventive drug use714 (53.0)48 (61.5)41 (70.7)1509 (8.5)67 (60.9)129 (73.3)Ever used CGRP mAb, n (%)Galcanezumab–45 (57.7)21 (36.2)–59 (53.6)81 (46.0)Fremanezumab–35 (44.9)27 (46.6)–61 (55.5)70 (39.8)Erenumab–33 (42.3)24 (41.4)–47 (42.7)50 (28.4)CGRP mAb calcitonin gene-related peptide monoclonal antibody, n number of respondents, NSAIDs Nonsteroidal anti-inflammatory drugs, OTC over-the-counteraNumber of participants: Eligible, No CGRP mAb = 1131; Eligible, Current CGRP mAb = 74; Eligible, Discontinued CGRP mAb = 53; Ineligible, Current CGRP mAb = 104; Ineligible, Discontinued CGRP mAb = 139; Ineligible, No CGRP mAb = 7015 Treatment patterns of study respondents General practitioner 396 (35.0) Headache Specialist 30 (40.5) General practitioner 24 (45.3) General practitioner 2253 (32.1) General practitioner 45 (43.3) General practitioner 53 (38.1) General practitioner 27 (36.5) CGRP mAb calcitonin gene-related peptide monoclonal antibody, n number of respondents, NSAIDs Nonsteroidal anti-inflammatory drugs, OTC over-the-counter aNumber of participants: Eligible, No CGRP mAb = 1131; Eligible, Current CGRP mAb = 74; Eligible, Discontinued CGRP mAb = 53; Ineligible, Current CGRP mAb = 104; Ineligible, Discontinued CGRP mAb = 139; Ineligible, No CGRP mAb = 7015 All respondents in the CGRP mAb-eligible groups, ineligible current and discontinued CGRP mAb groups, and 18.3% of the ineligible no CGRP mAb group had ever used preventive drugs. While current oral preventive drug use was common in all CGRP mAb-experienced respondents, CGRP mAb-discontinued users in the CGRP mAb-ineligible group had the highest proportion of respondents currently on oral preventive drugs (73.3%). Patient Perception and Attitude Towards Headache and Communication with Physicians Headache perception also differed by CGRP mAb eligibility and CGRP mAb experience (Table 4). Many (60.3–67.9%) of CGRP mAb-eligible and 38.1–48.2% of ineligible respondents perceived headache as “a disease that can only be endured until symptoms subside,” regardless of treatment status. Differences in treatment status were more evident in perceptions related to treatability. Perceiving headache as a “disease whose symptoms can be improved with medication” and “disease whose symptoms can be improved by lifestyle modification” was reported more frequently among current CGRP mAb users than among discontinued and no CGRP mAb users, in both eligibility groups. Table 4Headache perception, attitude toward headache management, and discussion of treatment goals with physicians among study respondentsEligibleIneligibleVariableNo CGRP mAb (n = 1348)Current CGRP mAb (n = 78)Discontinued CGRP mAb (n = 58)No CGRP mAb (n = 17,820)Current CGRP mAb (n = 110)Discontinued CGRP mAb (n = 176)Perception of headacheDisease that can only be endured until symptoms subside832 (61.7)53 (67.9)35 (60.3)7941 (44.6)53 (48.2)67 (38.1)More like a condition than a disease689 (51.1)29 (37.2)30 (51.7)8298 (46.6)44 (40.0)57 (32.4)Something to just accept the pain541 (40.1)35 (44.9)17 (29.3)4093 (23.0)32 (29.1)59 (33.5)Causes headache, but not a big deal510 (37.8)27 (34.6)32 (55.2)5813 (32.6)42 (38.2)69 (39.2)Disease caused by neurological abnormality469 (34.8)22 (28.2)25 (43.1)4258 (23.9)48 (43.6)60 (34.1)Disease whose symptoms can be improved by lifestyle modification379 (28.1)44 (56.4)18 (31.0)3236 (18.2)49 (44.5)51 (29.0)Disease influenced by lifestyle and diet377 (28.0)23 (29.5)25 (43.1)3852 (21.6)44 (40.0)70 (39.8)Can happen to anyone, nothing special/unusual366 (27.2)15 (19.2)12 (20.7)7462 (41.9)33 (30.0)53 (30.1)Disease whose symptoms can be improved with medication345 (25.6)42 (53.8)25 (43.1)2978 (16.7)48 (43.6)52 (29.5)Hereditary disease217 (16.1)21 (26.9)12 (20.7)1458 (8.2)27 (24.5)33 (18.8)Other47 (3.5)1 (1.3)1 (1.7)536 (3.0)1 (0.9)1 (0.6)Attitude towards headache managementI want to take action if there is an easy method available641 (47.6)17 (21.8)22 (37.9)7421 (41.6)36 (32.7)64 (36.4)I want to consult a doctor and change how I manage treatment375 (27.8)48 (61.5)25 (43.1)1667 (9.4)40 (36.4)32 (18.2)I would like to change somewhat, but not to the point of treatment194 (14.4)7 (9.0)9 (15.5)4978 (27.9)27 (24.5)57 (32.4)I cannot say/not applicable78 (5.8)2 (2.6)1 (1.7)1581 (8.9)–8 (4.5)I am fine (do not want to change)60 (4.5)4 (5.1)1 (1.7)2173 (12.2)7 (6.4)15 (8.5)Discussion of treatment goals with physiciansn = 936n = 74n = 53n = 4389n = 103n = 129Have never discussed treatment goals311 (33.2)11 (14.9)6 (11.3)2122 (48.3)5 (4.9)10 (7.8)Discuss treatment goals when there are changes158 (16.9)10 (13.5)9 (17.0)626 (14.3)19 (18.4)19 (14.7)Discuss treatment goals regularly, but not every time322 (34.4)30 (40.5)23 (43.4)1123 (25.6)44 (42.7)63 (48.8)Discuss treatment goals every time145 (15.5)23 (31.1)15 (28.3)518 (11.8)35 (34.0)37 (28.7)Data presented are n (%).CGRP mAb calcitonin gene-related peptide monoclonal antibody, n number of respondents Headache perception, attitude toward headache management, and discussion of treatment goals with physicians among study respondents Data presented are n (%). CGRP mAb calcitonin gene-related peptide monoclonal antibody, n number of respondents The respondents’ attitudes towards CGRP mAb therapy also varied by eligibility and CGRP mAb experience. Among CGRP mAb-eligible nonusers, the most frequently reported attitude was “I want to take action if there is an easy method” (47.6%), whereas “I want to consult a doctor and change how I manage treatment” was the most common attitude among eligible current CGRP mAb users (61.5%) and discontinued CGRP mAb users (43.1%) (Table 4). Regarding the discussion of treatment goals with physicians, CGRP mAb-eligible current users reported discussing “treatment goals every time” (31.1%), and a lower proportion among CGRP mAb-eligible nonusers (15.5%) (Table 4). Conversely, most eligible nonusers reported “never discussing treatment goals” (33.2%), than eligible current (14.9%) and discontinued users (11.3%). Barriers to CGRP mAb initiation Awareness of CGRP mAbs was notably low among respondents without CGRP mAb experience (Fig. 2). Among the eligible nonusers, 78.0% reported never having heard of CGRP mAbs, while 11.6% had heard the name and 10.4% knew what kind of medication it was. Among the CGRP mAb-ineligible nonusers, 92.4% had never heard of CGRP mAbs, 4.4% had heard the name, and only 3.1% knew what kind of medication it was. Awareness of CGRP mAbs among respondents without CGRP mAb experience. Eligible No CGRP mAb—respondents meeting CGRP mAb eligibility criteria at the time of the survey but had never used CGRP mAbs; ineligible No CGRP mAb—respondents not meeting eligibility criteria at the time of the survey and had never used CGRP mAbs. CGRP mAb calcitonin gene-related peptide monoclonal antibody Among those who had never used CGRP mAbs, very few reported having been introduced to these medications by a physician. Among CGRP mAb-eligible nonusers, only 4.2% had been introduced to CGRP mAbs by their doctor, whereas among ineligible nonusers, this proportion was even lower at 1.0%. Regarding the reasons for not using CGRP mAbs despite physician introduction (multiple responses allowed), the CGRP mAb eligible nonusers (n = 56) most frequently cited “worried about the cost” (37.5%), followed by “I wasn’t sure if it is worth the cost” (30.4%), “I was worried about side effects” (21.4%), “I don’t think the effect will be the same as the current treatment” (19.6%), and “there is no facility nearby that can prescribe it (the facility that can prescribe is far away)” (19.6%) (Fig. 3). In contrast, the CGRP mAb-ineligible nonusers (n = 186) most commonly reported that “I didn’t know if the treatment was right for my migraine” (22.6%), followed by “there is no facility nearby that can prescribe it (the facility that can prescribe is far away)”(19.4%), “I was satisfied with my current treatment” (18.3%), “I wasn’t sure if it would be worth the cost” (18.3%), and “worried about the cost” (17.7%) (Supplementary Table S3). Main reasons for not initiating CGRP mAbs referred by physician. Eligible no CGRP mAb—respondents meeting CGRP mAb eligibility criteria at the time of the survey but had never used CGRP mAbs; ineligible no CGRP mAb—respondents not meeting eligibility criteria at the time of the survey and had never used CGRP mAbs. CGRP mAb calcitonin gene-related peptide monoclonal antibody, n number of respondents CGRP mAb Discontinuation, Suspension, Resumption, and Switching A total of 234 respondents discontinued using CGRP mAbs, including 58 from the CGRP mAb-eligible group and 176 from the ineligible group. In the overall study respondents, the most common reason for discontinuation was “doctor advised to stop” (14.5%), “injection does not work or no longer works” (13.2%), and “information from the internet” (12.0%) (Fig. 4a). The most common reason for discontinuation among CGRP mAb-eligible groups were “the doctor advised me to stop” (20.7%), and “with information on the internet” (14.2%) among CGRP mAb-ineligible groups (Supplementary Table S4). CGRP mAb was suspended among 256 respondents, including CGRP mAb-eligible (37 current CGRP mAb and 38 discontinued CGRP mAb) and ineligible (68 current CGRP mAb and 113 discontinued CGRP mAb) groups. The most common reasons for the suspension of CGRP mAbs were “doctor advised to stop” (12.9%), “injection does not work or no longer works” (12.5%), and “injection was effective enough and thought I would stop” (12.5%) (Fig. 4b). Among the 256 respondents who resumed CGRP mAbs, including those eligible (37 current CGRP mAb and 38 discontinued CGRP mAb) and ineligible (68 current CGRP mAb and 113 discontinued CGRP mAb) groups, the most common reasons for resumption were “headache started to come back” (16.8%), “frequency of headache attacks increased” (15.6%), and “doctor suggested resuming” (12.5%) (Fig. 4c). The most frequent reasons for switching CGRP mAbs were “headache days increased with the previous injection” (14.7%), “doctor recommended to change” (13.2%) and “worried about side effects” (11.8%), and “thought current injection might work better” (11.8%) (Fig. 4d). Main reasons for CGRP mAb discontinuation, suspension, resumption, and switching. Black color indicates the top 3 reasons. CGRP mAb calcitonin gene-related peptide monoclonal antibody, N number of respondents Factors Associated with CGRP mAb Treatment Experience In the multivariate analysis, prior triptan use (OR 9.38 [5.94, 14.80]), consultation at the CGRP mAb-prescribing department (OR 7.20 [3.60, 14.37]), history of medication-overuse headache (OR 3.52 [2.04, 6.05]), history of diabetes (OR 2.95 [1.83, 4.76]), and history of hypertension (OR 2.76 [1.85, 4.13]) (all p < 0.001) were the key significant factors associated with CGRP mAb treatment experience (ever used [current and discontinued groups] versus never used) among CGRP mAb-eligible respondents (Fig. 5a). For the analysis of patients who visited a medical institution in the past year, visit to CGRP mAb prescribable department (OR 2.55 [1.30, 4.98]) and discussion of treatment goals (OR 2.95 [1.73, 5.02]) were statistically significant (Fig. 5b). Factors associated with the CGRP mAb treatment experience (ever used [current and discontinued CGRP mAb groups] versus never used). (a) Includes respondents eligible for CGRP mAbs but had no CGRP mAb experience (n = 1348) and respondents eligible for CGRP mAbs and had CGRP mAb experience (n = 136) and (b) Includes respondents who visited a medical institution in the past year: eligible for CGRP mAbs but had no CGRP mAb experience (n = 936), and respondents eligible for CGRP mAbs and had CGRP mAb experience (n = 127). Age was adjusted for sex, and vice versa; MIDAS and MIBS-4 were adjusted for age and sex; and all other variables were adjusted for age, sex, and MHD in the regression model. Red color indicates the variables that significantly (p < 0.05) affect CGRP mAb treatment experience. CGRP mAb calcitonin gene-related peptide monoclonal antibody, CI confidence interval, JPY Japanese Yen, MHD monthly headache days, MIBS-4 Migraine interictal burden scale-4, MIDAS Migraine disability assessment scale, MOH medication-overuse headache, NSAID nonsteroidal anti-inflammatory drugs, OR odds ratio In the variable selection sensitivity analysis using a p < 0.20 univariate entry threshold, only one additional variable (history of tension-type headache) qualified for inclusion in the multivariate model; its effect estimate did not reach statistical significance (OR 1.44 [0.99, 2.11], p = 0.059), and the estimates for all other variables were essentially unchanged. The current user sensitivity analysis results suggested prior triptan use (OR 11.21 [5.97, 21.05]), consultation at the CGRP mAb-prescribing department (OR 9.53 [3.45, 26.34]), history of medication-overuse headache (OR 4.61 [2.48, 8.57]), and patient perception of symptom improvable with preventive treatment (OR 3.55 [2.22, 5.68]) (all p < 0.001) were the key significant factors associated with eligible current CGRP mAb group versus eligible no CGRP mAb group (Supplementary Fig. S1a). For the analysis of patients who visited a medical institution in the past year, visit to CGRP mAb prescribable department (OR 3.03 [1.20, 7.63]) and discussion of treatment goals (OR 2.73 [1.41, 5.28]) were statistically significant (Supplementary Fig. S1b). Discussion This nationwide, population-based analysis of the OVERCOME (Japan) 2nd study demonstrated a substantial treatment gap in the utilization of CGRP mAbs among people with migraine in Japan. Despite meeting the eligibility criteria for CGRP mAb therapy based on the current symptom status at the time of the survey, approximately 90% of eligible individuals had never received treatment with CGRP mAbs, indicating that eligibility alone is insufficient to ensure treatment initiation and that additional factors influence real-world utilization. A recent analysis of the OVERCOME (US) study reported that 95.0% of people with migraine never used CGRP mAbs [39]. However, direct comparison of utilization rates between the current study and Ashina et al. [39] is limited by differences in study design and eligibility criteria, such as Japan’s OUGL criteria [29–31], which require prior oral preventive failure, whereas the US follows a broader eligibility criterion [51]; differences in drug pricing and reimbursement policies; healthcare system structure; and survey methodology. Nevertheless, the low overall utilization of CGRP mAbs across countries suggests that the treatment gap for individuals with migraine is a global health challenge, and not unique to the Japanese healthcare system. To our knowledge, this is the first study to describe the treatment gap in CGRP mAb utilization at a population level in Japan and to identify factors associated with treatment experience among CGRP mAb-eligible individuals. This study assessed the CGRP mAb eligibility based on the current symptoms at the time of survey, where “no CGRP mAb” group (90.8%) should be considered as “the untreated proportion within the patient group who continue to meet symptomatic criteria at the time of the survey.” However, all 422 CGRP mAb-experienced users were likely to have met OUGL criteria at treatment initiation. The 286 ineligible CGRP mAb-experienced users represent a mixed population including those whose symptoms improved due to treatment response, whose symptoms remitted after discontinuation, and those with mild symptoms who barely met eligibility criteria. If all experienced patients were included in the potentially eligible population based on symptom status at treatment initiation, the maximum potentially eligible population would be 1770, of whom 23.8% would be treatment-experienced and 76.2% untreated. Therefore, the true treatment gap is likely to lie between the current estimate of 90.8% and a lower-bound estimate of 76.2%. Additionally, the 90.8% nonuse among the technically eligible population may partially reflect the appropriate clinical gatekeeping under resource constraints, particularly given that ICHD-3-based eligibility assessed by online survey may overclassify patients relative to clinician assessment and patient preferences to avoid injectables and continue oral therapy. Among the 286 ineligible respondents with CGRP mAb experience, 110 in the current CGRP mAb group can be interpreted as those whose symptoms improved with treatment and likely fell below MHD/MIDAS thresholds at the time of the survey, but were continuing treatment as per clinical judgment, and 176 in the discontinued CGRP mAb group as those whose symptoms remained stable after discontinuation. The inclusion of current CGRP mAb users was consistent with the OUGL [29–31], which primarily defines initiation criteria. While the guidelines recommend periodic evaluation and possible discontinuation, it does not provide explicit quantitative thresholds for continuation; thus, patients who improved may no longer meet CGRP mAb initiation criteria at the time of assessment. Clinical evidence suggests that CGRP mAb discontinuation may worsen migraine frequency, disability, and burden or cause relapse [52–54]. Hence, continuing CGRP mAb therapy per clinical judgment, even after symptomatic improvement, is consistent with current clinical practice and evidence. Furthermore, the high mean MIBS-4 score of 7.6 in the ineligible current CGRP mAb group suggests that interictal burden persists, so treatment continuation could be clinically reasonable. The current study revealed notable differences in headache perception and management attitudes between CGRP mAb users and nonusers. Most eligible nonusers perceived headache as “a disease that can only be endured until symptoms subside,” suggesting that these perceptions may be associated with delayed engagement in seeking advanced preventive treatment. Additionally, the perception that headache can be modified with medications or lifestyle changes was more prevalent among current CGRP mAb users across both eligibility groups. Consistent with this, the multivariate analysis showed that the patient perception of symptom improvement with preventive treatment (OR 2.31; 95% CI 1.61, 3.33) was significantly associated with CGRP mAb treatment experience, suggesting that active treatment may be associated with both symptom alleviation and enhanced patients’ understanding of headaches as a manageable condition. Similar to perception, patients’ attitudes towards headache management also varied across treatment groups. CGRP mAb-eligible current and discontinued users more frequently expressed a desire to “consult a doctor and change how I manage treatment,” indicating a more proactive attitude toward headache management. In contrast, among CGRP mAb-eligible nonusers, the most frequently reported attitude was “I want to take action if there is an easy method,” reflecting an engagement influenced by convenience. Together, these findings suggest that the perceptions of headache as an uncontrollable condition, combined with limited awareness of available therapies, may contribute to the underutilization of CGRP mAbs in eligible patients. Furthermore, the frequency of discussing treatment goals with physicians differed substantially between groups. Eligible current users and discontinued users more frequently reported discussing treatment goals with their physician regularly, but not every time. The findings from the OVERCOME (Japan) 2nd study by Suzuki et al. [55] on patient-doctor communication reported that although 96.6% of respondents had treatment goals in mind, 36.0% had never discussed them with their doctors. The most common reason for not discussing with their doctors, was “I think the doctor will ask, if necessary, but they don’t particularly ask” (36.0%), highlighting the need for physicians to proactively initiate discussions about patient’s treatment goals and daily life expectations. Collectively, these observations suggest that the physician-patient communication may play an important role in facilitating the initiation of preventive treatment. Enhancing communication that addresses patients’ underlying perceptions and attitudes toward headaches, in addition to providing information about treatment options, may be essential to bridge the treatment gap. The study highlights low awareness of CGRP mAbs among eligible nonusers, as 78% reported they had never heard of CGRP mAbs. Furthermore, physicians informed only 4.2% of eligible nonusers about CGRP mAbs. These results suggest that a lack of patient awareness and insufficient physician-patient communication regarding treatment options may contribute to the treatment gap. A community-based campaign to raise awareness about headaches using leaflets reported an increase in the percentage of individuals who knew about headaches after the intervention [56]. Similarly, Akiyama et al. [57] demonstrated that a support video (“Talking Picture Book”) designed to address patients’ concerns about CGRP mAbs was effective in helping hesitant patients initiate galcanezumab, with 52.4% of viewers subsequently starting treatment. Their study also identified that patients’ willingness to try CGRP mAbs was a significant factor associated with treatment initiation (OR 9.82, p = 0.04), underscoring the importance of how physicians communicate information about these treatments. Among eligible nonusers who were informed about CGRP mAbs by their physicians, concern about cost was the most common reason for not initiating treatment (37.5%), followed by uncertainty about whether the treatment would be worth the cost (30.4%). These findings suggest that the challenge is not simply the cost itself, but rather patients’ difficulty in recognizing the value of the treatment relative to its cost. Previous OVERCOME (Japan) studies have documented the extent of losses migraine causes in daily life, including decreased work productivity, limited family, social, and leisure activities, leading to physical or mental stress and reduced quality of life [6, 58]. Furthermore, Takeshima et al. [59] suggested that migraine also has a measurable impact on the daily lives of patients’ cohabiting family members. Similarly, Suzuki et al. [60] reported that although family members felt compassion for patients with migraine, the patients themselves tended to feel resignation and endurance due to perceived lack of understanding from those around them. This may cause patients to undervalue the potential benefits of migraine preventive treatment, perceiving CGRP mAb therapies as not worthy of the cost. Together with the findings on patient perception and attitudes described above, these results underscore that effective communication between physicians and patients about the benefits, expectations, and treatment goals of CGRP mAb therapy, potentially supplemented by educational materials, is essential to facilitate informed shared decision-making. The study also described the reasons for discontinuation, suspension, and resumption of CGRP mAb therapy in Japan. Physician recommendations to stop, perceived lack of efficacy, and information from the internet were the most common reasons for discontinuation. Previous clinic-based studies in Japan have reported slightly divergent perspectives on discontinuation of CGRP mAbs. A survey by Takizawa et al. [62] among JHS members found that “enough improvement of migraines” (54.2%) and “high cost” (24.2%) were the most frequently reported reasons by treatment responders for discontinuing CGRP mAbs. This apparent difference between physician-reported and patient-reported reasons may reflect the different survey populations, as well as potential overlap between “doctor advised to stop” and sufficient clinical improvement. In the present study, CGRP mAb-experienced ineligible respondents showed lower MIDAS severity but reported elevated MIBS-4 scores. Although MIDAS is a well-validated measure of migraine-related disability in Japanese patients, its 3-month recall format may diverge from prospectively recorded burden [47], and MIDAS-defined disability is influenced by psychiatric comorbidity independent of attack frequency [61]. A reduction in MIDAS therefore does not necessarily indicate improved migraine pathophysiology, especially when the elevated MIBS-4 shows persistent interictal burden. This suggests that physicians’ decisions to discontinue treatment may have been influenced primarily by guideline-aligned deprescribing, reductions in headache or migraine days without considering the persistent interictal burden, cost-driven decisions not captured in the patient’s self-report, and incomplete assessment of treatment response. Nonetheless, the high MIDAS total score for CGRP mAb-eligible discontinued users (46.0), prompts concerns about whether discontinuation was appropriate given the residual symptoms. Interestingly, in the current study, physician recommendation was also a key factor in treatment resumption, along with headache recurrence and increased attack frequency. These findings highlight the central role of physicians in guiding treatment decisions throughout CGRP mAb therapy. Ashina et al. [39] also identified current use of botulinum toxin for migraine as the factor most strongly associated with continuing CGRP mAb use (OR 4.53 [3.14-6.55]). This finding suggests that patients receiving multimodal preventive therapy, including both botulinum toxin and CGRP mAbs, may be more likely to maintain CGRP mAb treatment, possibly reflecting greater disease severity, stronger engagement with specialty care, or synergistic therapeutic benefits. The high resumption rate observed in both our study and Tanei et al.’s study [63] suggests that many patients who discontinue CGRP mAbs eventually resume it, often associated with headache recurrence, indicating the ongoing need for effective preventive therapy in this population. The multivariate analysis identified consultation at CGRP mAb prescribable departments as one of the strongest factors associated with CGRP mAb treatment experience among eligible respondents who had used CGRP mAb. Current CGRP mAb-eligible users were more likely to have visited headache specialists or neurologists, whereas eligible nonusers predominantly consulted general practitioners (GP) such as family medicine or internal medicine physicians. These findings suggest that access to appropriate specialists may play a role in CGRP mAb treatment initiation. Prior triptan use was also significantly associated with CGRP mAb treatment experience, suggesting that CGRP mAbs are potentially introduced as a step-up therapy for patients who have already tried prescription acute treatments. Similarly, in the OVERCOME (US) study, current use of recommended acute medication (OR 2.43 [2.09–2.82]), and contraindications to triptan use (OR 2.32 [2.06–2.60]) were the top significant factors associated with CGRP mAb ever-users [39]. These parallel findings across two distinct healthcare systems underscore the consistent role of prior acute treatment experience as a gateway to CGRP mAb initiation, regardless of differences in prescribing regulations and reimbursement criteria. The history of medication-overuse headache was also significantly associated with CGRP mAb experience in the current study, indicating that overuse of acute medications may prompt consideration of preventive treatment with CGRP mAbs. Notably, cardiovascular comorbidities, including hypertension and diabetes, were associated with higher CGRP mAb treatment experience. This may reflect that patients with cardiovascular risk factors, for whom triptans are contraindicated or require caution, are more likely to be directed toward CGRP mAb therapy as an alternative preventive option. This observation is consistent with the US OVERCOME study finding that triptan contraindications were significantly associated with CGRP mAb use [39], suggesting that cardiovascular comorbidities may serve as an indirect pathway to CGRP mAb treatment through triptan ineligibility in both countries. Additionally, patients with cardiovascular disease may be more engaged with the healthcare system [64]. With regular physician consultations, comorbidities, including migraines, could be more readily identified, and specialist referral and prescribing relationships could be more established. However, the current cross-sectional study design cannot elucidate why cardiovascular comorbidities were associated with high CGRP mAb treatment experience. Female sex was associated with lower odds of CGRP mAb treatment experience in the current study, although migraine is more prevalent among women than among men in Japan [5, 6]. A previous OVERCOME (Japan) 2nd analysis also reported a high migraine burden among females with lower use of CGRP mAb and other oral preventive medications compared with males [65]. Similar observations were reported in the OVERCOME (US) study, where CGRP mAb ever use was less frequent among females [39]. These findings suggest a signal of potential sex-based disparities in access to CGRP mAb therapy for women, regardless of healthcare system differences or geographical regions. Potential explanations for this observation include differences in healthcare-seeking behavior [66], normalization of headache symptoms among women, or socioeconomic factors [67, 68] that may differentially affect women’s access to specialist care. Further research is needed to elucidate the underlying factors contributing to this disparity. Our findings have important clinical implications for addressing the treatment gap in CGRP mAb utilization in Japan. First, improving access to specialists who can prescribe CGRP mAbs, such as headache specialists and neurologists, is essential. This may involve strengthening referral networks from primary care and raising awareness among GPs about when to refer patients for specialized migraine care. Additionally, authorities should take steps to raise awareness among fellows of the Japanese Society of Internal Medicine who are allowed to prescribe CGRP mAbs. Second, enhancing physician-patient communication about CGRP mAb therapy, including treatment goals, expected benefits, and realistic expectations, is crucial for facilitating informed treatment decisions. Moreover, raising awareness on migraine and management may improve patients’ perception and understanding of the burden and losses caused by migraine. The use of educational materials, such as the support video described by Akiyama et al. [57], may be a useful adjunct to physician explanations. Third, physicians should proactively address patients’ concerns about treatment, including those arising from information obtained outside the clinical setting, to ensure that treatment decisions are based on accurate, evidence-based information. The recent JHS position statement [40] recommending CGRP-targeting therapies as a first-line option for migraine prevention may help increase awareness and reduce barriers to treatment initiation. Future studies should evaluate whether this guideline change improves access to CGRP mAb therapy among eligible patients. Limitations This study has several limitations. The cross-sectional design precludes causal inferences regarding the factors associated with CGRP mAb treatment experience. All data were self-reported, which may introduce recall bias, and medical diagnoses were not confirmed by medical records. The online survey methodology may have excluded older adults and individuals with low digital literacy or who lack internet access. On the other hand, this may partly reflect the low prevalence of migraine in older adults, as the demographic profile of the parent OVERCOME (Japan) 2nd study showed a mean age of 40.5 years with 68.8% female respondents [6]; consistent with established Japanese migraine epidemiology wherein independent population-based surveys show female predominance and a peak in their 30s and 40s [2, 3]. Consequently, CGRP mAb access and awareness may also be low among older adults. The treatment-gap estimate in this study is therefore likely an underestimate relative to the true population, including older adults. The CGRP mAb-eligible population may have been overestimated because prior oral preventive failure was defined using self-reported treatment history rather than strict OUGL-defined failure criteria. In this study, prior oral preventive use was used as a proxy for treatment failure, potentially classifying some patients with ongoing effective oral preventive treatment as CGRP mAb-eligible. On the other hand, the CGRP mAb-eligible population may also have been underestimated, as patients who had not received oral preventive treatments owing to contraindications or safety concerns would have been classified as ineligible for CGRP mAb. Thus, misclassification may have occurred in both directions. Furthermore, because eligibility was assessed on the basis of current symptom status at the time of the survey, respondents who benefited from CGRP mAb therapy initiated before the survey might have been classified as ineligible due to symptom improvement, potentially leading to an overestimation of the treatment gap in the eligible group. The true magnitude of the untreated proportion is estimated to range from 76.2 to 90.8%. However, the exact number of patients who were considered ineligible due to successful treatment cannot be determined, due to the cross-sectional study design. Additionally, the migraine diagnostic criteria using modified ICHD-3 in the current study were based on the validation studies conducted in US populations, and independent validation in the Japanese population was not performed. The diagnosis of migraine was based on the patient’s self-report rather than clinician judgment, which may lead to misclassification between tension-type headache and migraine. Moreover, the proportion of migraine with aura (41.2%) reported in the primary OVERCOME (Japan) 2nd study by Danno et al. [6] was higher than that reported in Japanese epidemiologic surveys (0.7–2.6%) [2, 3], suggesting migraine diagnoses may be partially over-classified due to the nature of online surveys. Additionally, misclassifying tension-type headache as migraine could theoretically inflate the treatment gap estimate; however, the directional impact is likely modest. The spectrum study by Lipton et al. [69] found that 32% of patients who were clinically labeled as disabling episodic tension-type headache were reclassified as migraine after the neurologist reviewed diary analysis, and tension-type headache and migraine are recognized to share trigeminovascular pathophysiology and central sensitization mechanisms [70]. Individuals potentially misclassified may therefore represent migraine without aura with reduced symptom expression rather than a truly distinct population, limiting the net effect on our estimates. Finally, the survey was conducted in 2023, prior to the release of the JHS position statement [40] recommending CGRP-targeting therapies as first-line prevention and therefore does not reflect potential changes in clinical practice following this guideline update. Conclusions This population-based analysis revealed that approximately 90% of CGRP mAb-eligible individuals with migraine in Japan had never received CGRP mAb therapy, highlighting a substantial treatment gap. Low patient awareness, limited access to CGRP mAb-prescribing specialists, and insufficient physician-patient communication about treatment options and goals were identified as key factors contributing to this gap. Furthermore, we identified novel insights regarding the reasons for discontinuation, suspension, and resumption of CGRP mAb therapy from a population-based perspective. Improving referral pathways to appropriate specialists, raising awareness on standard migraine therapy to GPs and patients, and ensuring access to treatment options based on appropriate clinical judgment are essential to address the unmet treatment needs of people with migraine in Japan. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 258 KB) Acknowledgements The authors thank the participants of the OVERCOME (Japan) 2nd study for providing valuable insights. Swetha R Reghunath, an employee of Eli Lilly and Company, Lilly Bengaluru, India, provided medical writing assistance. Abbreviations Calcitonin gene-related peptide monoclonal antibody General practitioner Healthcare resource utilization Monthly headache day Migraine Interictal Burden Scale-4 Migraine Disability Assessment Scale Non-steroidal antiinflammatory drug Over-the-counter Patient-reported outcome Standard deviation United States Funding This study was funded by Eli Lilly Japan K.K. and Daiichi Sankyo Company, Limited. Declarations Conflict of Interest Yoshiki Hanaoka received speaker honoraria from Eli Lilly Japan K.K. Tsubasa Takizawa is a consultant/advisor and/or serves on an advisory board for Amgen K.K., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Teijin Pharma Limited. He received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and UCB Japan Co. Ltd.; and grant/funding from Eli Lilly Japan K.K., Pfizer Japan Inc., and Tsumura & Co. outside the submitted work. Ryotaro Ishii has served as a consultant for Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., and Otsuka Pharmaceutical Co., Ltd; and received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Daisuke Danno received advisory fees from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Lundbeck; and honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Masayuki Hamakawa is an employee of Social Survey Research Information Co., Ltd. Social Survey Research Information Co., Ltd. performed data collection and statistical analyses in this study and was sponsored by Eli Lilly Japan K.K. Kaname Ueda, Yoshinori Tanizawa, Satoshi Osaga, and Chie Hashimoto are employees of Eli Lilly Japan K.K. and may own stock/stock options of Eli Lilly and Company. Leo J. Philip Tharappel is an employee of Eli Lilly and Company and may own stock/stock options of Eli Lilly and Company. Ethics Approval and Consent to Participate The Medical Corporation TOUKEIKAI Kitamachi Clinic ethics committee approved this study (number BGQ09531) on April 19, 2023. The study was conducted per ethical principles originating from the Declaration of Helsinki, and that were consistent with Good Pharmacoepidemiology Practices. All applicable Japanese laws and regulations were followed. All survey respondents provided electronic informed consent and agreed to participate in the study. Consent for Publication Not applicable Availability of Data and Materials The datasets generated and/or analyzed during the current study are available at Eli Lilly Japan K.K on reasonable request. Author Contributions Conceptualization: YH, KU, YT, CH; Methodology: SO, YT, LPT; Data curation: MH; Formal analysis: YH, DD, RI, TT, MH, SO, KU, YT, LPT, CH; writing—original draft: LPT; or writing—review and editing: YH, TT, RI, DD, MH, KU, YT, LPT, CH. All authors reviewed and approved the submitted version and agreed to be accountable for their contributions. References Associated Data Supplementary Materials Supplementary file1 (PDF 258 KB) Data Availability Statement The datasets generated and/or analyzed during the current study are available at Eli Lilly Japan K.K on reasonable request.